Brought to you by 
Astex, AstraZeneca evaluate AZ's compounds
11 Jun 2001
Executive Summary
Astex Technology, a specialist in high-throughput x-ray crystallography, has agreed to screen AstraZeneca's compounds to determine those most likely affected by cytochrome P450 interactions.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
-
Drug Discovery Tools
- ADMET
- Bioinformatics
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com